89239-83-8

Upstream product

• 4027-57-0 ethyl 5-methyl-2H-pyrazole-3-carboxylate 
• 89239-82-7 ethyl 3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-5-carboxylate 

Downstream Products

• 89239-84-9 5-methyl-4-nitro-2-(2,2,2-trifluoroethyl)-2H-pyrazole-3-carboxylic acid 
• 1005780-73-3 N-[3-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)phenyl]-3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-5-carboxamide 
• 1318756-67-0 N-[2-(3-chloro-5-fluorobenzyl)-4-methyl-1,3-thiazol-5-yl]-3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazole-5-carboxamide 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines

Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines and pharmaceutically acceptable salts are described. These compounds are antipsychotic agents. Methods for their preparation, pharmaceutical compositions which contain them and methods for using said compositions are also described.